Peptide profile
TB-500 (Recovery)
Thymosin beta-4 for injury recovery
Compare TB-500 (Recovery) with other peptides →Summary
Thymosin beta-4 for systemic recovery & inflammation reduction.
- Typical dose
- 2-5mg Weekly
- Route
- Subcutaneous
- Cycle length
- 4-6 weeks
- Evidence
- Animal data
Mechanism
How it works
TB-500 acts like a freight train for repair cells — it moves large numbers of healing cells to where they're needed.
TB-500 binds to actin, supporting cell migration to injury sites and promoting angiogenesis.
Reported in research
Benefits
- Reduces systemic inflammation
- Accelerates multiple injury healing
- Improves recovery after surgery
- Promotes cell migration
Context, not a prescription
Dosing
- Typical range
- 2-5mg Weekly (Subcutaneous)
- Cycle length
- 4-6 weeks
Safety
Side effects & contraindications
Possible side effects
- Injection site pain
- Mild fatigue
- Nausea
- Flushing
Contraindications
- Active cancer
- Pregnancy
Research information, not medical advice. Always consult a licensed clinician before considering any peptide.
In depth
Full profile
What it does
Faster multi-site healing, reduced inflammation.
How it works
TB-500 acts like a freight train for repair cells — it moves large numbers of healing cells to where they're needed.
Promotes endothelial and fibroblast migration.
What to expect
Inflammation reduction in 1-2 weeks.
- Weeks 1-2: Reduced systemic inflammation.
- Weeks 3-4: Accelerated healing.
Good to know
- Start with lower dose
Staying safe
- Injection site pain
- Mild fatigue
Avoid if you have:
- Active cancer
- Pregnancy
Mechanism of action
TB-500 binds to actin, supporting cell migration to injury sites and promoting angiogenesis.
Promotes endothelial and fibroblast migration.
Pharmacodynamics
Inflammation reduction in 1-2 weeks.
Faster multi-site healing, reduced inflammation.
Timeline
- Weeks 1-2: Reduced systemic inflammation.
- Weeks 3-4: Accelerated healing.
Comparisons
- TB-500 — effectiveness Moderate, safety Good, cost $$, Medium to use
- BPC-157 — effectiveness High, safety Good, cost $$, Medium to use
Adverse effects
Common:
- Injection site pain
- Mild fatigue
Rare:
- Nausea
- Flushing
Contraindications & risk mitigation
Contraindicated in:
- Active cancer
- Pregnancy
- Start with lower dose
Qué hace
Curación más rápida en múltiples sitios, reducción de la inflamación.
Cómo funciona
TB-500 actúa como un tren de carga para las células reparadoras: transporta grandes cantidades de células de curación a donde se necesitan.
Promueve la migración endotelial y de fibroblastos.
Qué esperar
Reducción de la inflamación en 1-2 semanas.
- Semanas 1-2: Reducción de la inflamación sistémica.
- Semanas 3-4: Curación acelerada.
Bueno saber
- Comenzar con una dosis menor
Manteniéndose seguro
- Dolor en el sitio de inyección
- Fatiga leve
Evitar si tienes:
- Cáncer activo
- Embarazo
Mecanismo de acción
TB-500 se une a la actina, apoyando la migración celular hacia los sitios de lesión y promoviendo la angiogénesis.
Promueve la migración endotelial y de fibroblastos.
Farmacodinamia
Reducción de la inflamación en 1-2 semanas.
Curación más rápida en múltiples sitios, reducción de la inflamación.
Cronología
- Semanas 1-2: Reducción de la inflamación sistémica.
- Semanas 3-4: Curación acelerada.
Comparaciones
- TB-500 — efectividad Moderada, seguridad Buena, costo $$, Media de usar
- BPC-157 — efectividad Alta, seguridad Buena, costo $$, Media de usar
Efectos adversos
Comunes:
- Dolor en el sitio de inyección
- Fatiga leve
Raros:
- Náuseas
- Enrojecimiento
Contraindicaciones y mitigación de riesgos
Contraindicado en:
- Cáncer activo
- Embarazo
- Comenzar con una dosis menor
Reference data
Specifications
- Route
- Subcutaneous
- Cycle length
- 4-6 weeks
FAQ
Common questions
Can TB-500 be used with BPC-157?
Yes, commonly stacked for synergistic recovery.
What is the evidence level?
This compound is classified as Animal data. Most data comes from preclinical animal studies. Human clinical trial evidence is limited or absent.
Research
Research & sources
Current evidence for TB-500 (Recovery) is rated as Animal data. Research is based primarily on animal models.
- 1. Thymosin beta-4 in injury (2005) — DOI:10.1586/17434440.2.6.729
- 2. Thymosin beta-4 in injury (2005)